By the Top Tier Newswire AI Desk · September 10, 2026 at 10:26 AM ET · reviewed against 11 wire stories
BIOHAVEN LTD (BHVN) is down -15.60% in the latest session. Our newswire has captured 11 stories on BHVN across 9 sources in the last 36 hours, with AI sentiment reading bearish (avg 36/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BHVN stock is down today
Biohaven Ltd shares fell 15.60% to $12.66 in the session, driven by a partial clinical hold placed by the U.S. Food and Drug Administration on the company’s BHV-7000 trial program. The development led to a significant gap down at the open and continued pressure throughout the session. The FDA’s action paused new patient enrollment in the BHV7000-303 trial following nonclinical findings in rodents, though dosing of already randomized patients remains ongoing.
What Happened
The FDA issued a partial clinical hold on Biohaven’s BHV-7000 program, which is being developed as a treatment for focal epilepsy. The agency cited the need for additional nonclinical studies after identifying a specific metabolite in rodent trials. Biohaven confirmed the partial hold but noted that the ongoing dosing of patients already enrolled in the opakalim program is not affected. The announcement came amid heightened regulatory scrutiny and raised concerns about the drug’s development timeline and potential commercial viability.
What The Data Shows
The stock opened at $12.40, a 17.3% drop from the prior close of $15.00, and traded as low as $12.30 before bouncing slightly to $12.68 at the close of the session. Volume was 2.0 million shares, or 0.7 times the 3-month daily average. Over the past 8 sessions, the stock has declined 3.0% from $15.41 to $14.94. The stock also printed six fresh 52-week lows on September 10, 2026, indicating ongoing pressure from market participants.
What To Watch
Biohaven has no scheduled earnings date in the near term. Investors will need to monitor the breadth of coverage in the coming days, particularly any updates on the status of the BHV-7000 program and the FDA’s requirements for resuming enrollment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BHVN · Sep 10 session (5-min) · -14.67% vs prior close · updated 8:48 PM ETAI sentiment, last 36h · averaged over 11 stories · 36/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
2d agoInvestorsHubBEARISH 34Product/PR
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
Biohaven shares fall 17% after the FDA places a partial clinical hold on BHV-7000 trials, pausing new enrolment pending additional nonclinical studies.
2d agoThe FlyBEARISH 35Earnings
Biohaven falls -15.3%
2d agoStocktwits NewsBEARISH 34General
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?
Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite.
2d agoInvestors.comBEARISH 32General
Biohaven's Ratty Setback; How Xenon Benefits
2d agoInvestors.comBEARISH 28General
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.
3d agoMorningstarBEARISH 38General
Biohaven Shares Fall Premarket on Partial FDA Hold on BHV-7000
Biohaven said dosing of already randomized patients is allowed to continue across the opakalim program, adding that the partial hold has no impact on its BHV7000-303 focal epilepsy study, as enrollment and randomization was already completed. The company said it still expects topline data from the study by the end of the year.
3d agoMarketWatchBEARISH 34General
Biohaven: FDA Issues Partial Clinical Hold Letter on BHV-7000 Program >BHVN
3d agoInvesting.com MarketsBEARISH 38General
Why is Biohaven Pharmaceutical stock sliding today?
Why is Biohaven Pharmaceutical stock sliding today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →